Directors

	Norman Lott BSc ACA Finance Director and Company Secretary Norman Lott qualified as a chartered accountant in 1980 with Ernst & Whinney and joined Peat Marwick Mitchell & Company in their Hong Kong office in 1981. From 1984 onwards he held a number of senior financial positions in commerce and industry before joining Tiger Books International Plc in 1993 as finance director and was subsequently appointed as deputy managing director. He joined the Board of ReGen as Finance Director in June 1999 and continues in that role with ReGen Therapeutics Limited.
	Timothy Shilton BSc Hons Chief Executive Officer Tim Shilton has been involved in the pharmaceutical industry for over 20 years. After completing his degree at Surrey University in 1979 Tim joined the regulatory affairs department at Wellcome, where he was specifically involved in product registration and licensing. He later transferred to international strategic marketing/new products, where he was part of the team responsible for establishing Wellcome as the market leader in antivirals with Zovirax (aciclovir) and Retrovir (AZT). After leaving Wellcome in 1995 Tim consulted for various pharmaceutical and healthcare communications companies, before joining Phairson Medical in 1996, as product development and marketing director. Tim joined ReGen in November 2000 as Development Manager and was appointed to the Board as Development Director on 10th December 2002. Tim was appointed CEO of ReGen Therapeutics Limited upon its demerger in February 2011.
	Professor Marian L Kruzel PhD Company's Chief Scientific Consultant Professor Marian Kruzel is a faculty member of the Department of Integrative Biology and Pharmacology, The University of Texas, Medical School at Houston. He is an internationally recognized immunologist with an established interest and expertise in inflammation and age-related pathophysiology. He is the recipient of numerous grants and a participant in NIH funded projects. Also, he serves as a reviewer on several scientific journals, including Clinical and Experimental Immunology, Cellular and Molecular Biology Letters, and Journal of Experimental Therapeutics and Oncology. In 1999 Prof. Kruzel founded PharmaReview Corporation, a consulting firm that provides guidance to bio-medical research companies in various project design and development of clinical protocols. He is the former chairman of the board of Cancer Coalition of America. Through a consultancy agreement with the company Prof. Kruzel advises the Board on scientific research and development matters.
	Percy Lomax BSc (Econ) Key Consultant Percy Lomax joined the commercial intelligence department of Allen & Hanbury’s, part of the Glaxo Group, in July 1967 and has been involved in the drug industry since then, either as an adviser or an employee. He was stockbroker in August 1987 to the flotation of Medirace Plc, which became Medeva Plc. As a healthcare analyst at Robert Fleming and Co he worked on the second fund raising for Wellcome in 1992. In 1995 he co-founded PolyMasc Pharmaceuticals Plc and was instrumental in its flotation in December of that year. In 1996 he was responsible for the rescue rights issue of Proteus Plc and the flotation of Oxford BioMedica plc. He joined the Board of ReGen prior to the flotation. He became a consultant to ReGen Therapeutics Limited upon its demerger in February 2011.
back to top